fig5
From: Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
Figure 5. PFS of ICIs in KRAS-mutant NSCLC: (A) PFS in tumors with WT NSCLC or KRAS-mutant NSCLC; (B) PFS by PD-L1 expression levels; and (C) PFS by treatment modality. ICIs: Immune checkpoint blockades; PFS: progression-free survival; WT: wild type; KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NSCLC: non-small-cell lung cancer.
